A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2019
At a glance
- Drugs RPh 201 (Primary)
- Indications Optic nerve disorders
- Focus Registrational; Therapeutic Use
- Sponsors Regenera Pharma
- 02 Aug 2018 According to a Regenera media release, the final data from this study is expected in Q4 2019.
- 31 Jul 2018 According to a Regenera media release, the first patient for this trial has been enrolled in July 2018.
- 25 Jul 2018 Status changed from not yet recruiting to recruiting.